SAMANSIC-RP Precision Nutrition Specification

A Dual-Layer Biological Resilience Protocol for Artificial Microgravity Environments

​

1. Product Identification

• Product Name: SAMANSIC-RP Precision Nutritional System

• Product Code: SAMANSIC-RP/MG-1.0

• Product Classification: Investigational precision nutritional protocol (not a pharmaceutical drug)

• Target Population: Personnel with bilateral retinitis pigmentosa (RP, ICD-10 H355.2) operating in artificial microgravity environments, including space analogue missions, centrifuged habitats, and long-duration spaceflight.

• Framework Integration: The product integrates two interdependent layers: the biological layer (SAMANSIC-RP Protocol) for direct retinal and cellular protection, and the systemic-intelligence layer (Sovereign Biological Resilience Framework) for population-level immune and adaptive resilience.

​​

​

2. Intended Use and Performance Objectives

​

2.1 Primary Indication

• The SAMANSIC-RP Precision Nutritional System is intended to support remaining retinal cells, reduce oxidative stress, and possibly slow the progression of retinitis pigmentosa in personnel exposed to artificial microgravity conditions.

​​

2.2 Secondary Performance Objectives

• Photoreceptor protection: Mechanism: Glutathione replenishment and oxidative stress neutralization. Performance target: Reduce rate of ellipsoid zone (EZ) width loss by at least 30% versus untreated controls over 45 months.

• Mitochondrial support: Mechanism: ALA and CoQ10 supplementation. Performance target: Improve mitochondrial function markers in retinal and skeletal muscle tissue.

• Immune resilience: Mechanism: Gut-brain-SUMO axis fortification. Performance target: Maintain interferon signaling and NF-κB pathway integrity under microgravity stress.

• Neuroprotection: Mechanism: Citicoline and B-vitamin support. Performance target: Preserve visual acuity and retinal light sensitivity.

• Systemic adaptation: Mechanism: SUMOylation homeostasis. Performance target: Prevent microgravity-induced SUMO pathway dysregulation.

​

2.3 Contraindications

• Known hypersensitivity to any formula component

• Concurrent warfarin therapy (CoQ10 interaction risk)

• Active liver disease (high-dose NAC requires monitoring)

• Vitamin E supplementation exceeding 30 IU/day (must be discontinued)

​

​

3. Biological Rationale: The Dual-Layer Mechanism

​

3.1 Layer One: Retinal Oxidative Defense (SAMANSIC-RP Protocol)

• In retinitis pigmentosa, progressive rod photoreceptor degeneration creates a toxic oxidative environment. Rods outnumber cones by a 95:5 ratio; after rod loss, oxygen utilization in the outer retina drops markedly while oxygen supply remains unchanged, producing excess tissue oxygen that drives oxidative damage to surviving cones. This oxidative stress is the primary driver of secondary cone degeneration and the associated loss of central vision and visual field.

​

• N-acetylcysteine (NAC) directly counters this process. As a glutathione precursor, NAC replenishes the retina's primary antioxidant defense. In animal models of RP, oral NAC reduced oxidative damage to cones and promoted maintenance of cone function and survival. A Phase I clinical trial in RP patients found that oral NAC for six months was well-tolerated and produced a small but statistically significant improvement in visual acuity and retinal light sensitivity. The ongoing Phase III "NAC Attack" trial, which recruited 485 eligible RP patients from 31 clinical sites across seven countries by August 2025, is evaluating NAC at 1,800 mg twice daily over 45 months to determine if it can delay disease progression.

​

3.2 Layer Two: Systemic SUMOylation Homeostasis (Sovereign Biological Resilience Framework)

• Microgravity induces significant regulatory changes in cellular SUMOylation, the post-translational modification that regulates DNA repair, cytoskeletal dynamics, cell division, and protein turnover—all processes affected by spaceflight. A proteomic study of cells under simulated microgravity identified 347 SUMOylated proteins, with 18 demonstrating a 50% change in abundance under microgravity conditions. These findings underscore the pivotal role of SUMOylation in orchestrating cellular adaptation to microgravity stress and reveal potential targets for mitigating spaceflight-induced health risks.

​

• Microgravity is also associated with immunological dysfunction. Single-cell analysis of human peripheral blood mononuclear cells exposed to simulated microgravity revealed alterations in pathways for optimal immunity, including the cytoskeleton, interferon signaling, pyroptosis, innate inflammation, and sirtuin signaling. Microgravity directs monocyte inflammatory parameters and impairs T cell and NK cell functionality.

​

• The SAMANSIC-RP formula addresses these challenges through the gut-brain-SUMO axis concept: systemic support for SUMO protein production, combined with nutritional precursors for immune signaling pathways. NAC plays a dual role, supporting both retinal glutathione and systemic SUMOylation homeostasis. Magnesium, as a cofactor for SUMO-activating enzymes, supports the cellular stress response. Alpha-ketoglutarate (AKG) addresses the microgravity-induced decrease in alpha-ketoglutarate levels observed in metabolic studies, supporting mitochondrial function and the TCA cycle.

​

3.3 Artificial Microgravity Considerations

• Artificial microgravity environments (simulated via rotating wall vessels, clinostats, or centrifuged habitats) reproduce many of the cellular effects of true microgravity, including cytoskeletal alterations, mitochondrial dysfunction, and oxidative stress. The use of centrifugation to exert forces that partially or fully mimic Earth-level gravity has been shown to attenuate the transcriptomic response to microgravity in optic nerve and retinal tissue in a dose-dependent manner. However, even partial gravity environments present unique challenges, and the SAMANSIC-RP formula is designed to provide nutritional support that complements mechanical countermeasures.

​

​

4. Formulation and Composition

​

4.1 Active Ingredients

• N-Acetylcysteine (NAC): 1,800 mg twice daily. Mechanism: Glutathione precursor; SUMOylation support. Evidence level: Phase III trial ongoing (NAC Attack).

• Alpha-Lipoic Acid (ALA): 300 mg twice daily. Mechanism: Mitochondrial antioxidant; regenerates other antioxidants. Evidence level: Preclinical and reviews.

• Coenzyme Q10 (CoQ10): 150 mg twice daily. Mechanism: Mitochondrial electron transport; ATP production. Evidence level: Clinical (RP patients).

• Citicoline: 250 mg twice daily. Mechanism: Acetylcholine synthesis; membrane integrity. Evidence level: Clinical (retinal disease).

• Goji Berry Extract: 250 mg twice daily. Mechanism: Polysaccharide antioxidants; anti-inflammatory. Evidence level: Phase II (modest visual acuity improvement).

• Vitamin B6 (Pyridoxine): 50 mg once daily. Mechanism: Neurotransmitter synthesis; homocysteine reduction. Evidence level: NUTRARET trial.

• L-5-Methyltetrahydrofolate: 800 mcg once daily. Mechanism: Methyl donor; homocysteine reduction. Evidence level: NUTRARET trial.

• Methyl-cobalamin (B12): 1,000 mcg once daily. Mechanism: Homocysteine metabolism; myelin support. Evidence level: NUTRARET trial.

• Vitamin D3: 2,000 IU once daily. Mechanism: Neuroprotection; immune modulation. Evidence level: Conditional (only if deficient).

• Magnesium Glycinate: 200 mg once daily. Mechanism: NMDA regulation; SUMO enzyme cofactor. Evidence level: General neural support.

• Alpha-Ketoglutarate (AKG): 300 mg twice daily. Mechanism: TCA cycle; mitochondrial function. Evidence level: Microgravity preclinical.

​

4.2 Critical Exclusions

• Vitamin E: Excluded because studies suggest it may accelerate RP progression; RP patients should avoid more than 30 IU per day.

• High-dose Vitamin A: Excluded because newer analyses have not confirmed benefit and there is a risk of liver toxicity.

• Ashwagandha, Rhodiola, L-theanine, L-tyrosine, Phosphatidylserine, Acetyl-L-carnitine, Tulsi: Excluded because there is no direct RP evidence; omitted to reduce complexity and potential interactions.

​

4.3 Formulation Form

• Morning dose: Effervescent tablets (NAC-containing components) plus capsule complex.

• Evening dose: Effervescent tablets plus capsule complex.

• Total daily NAC dose: 3,600 mg (consistent with NAC Attack trial protocol).

​

​

5. Administration Protocol

​

5.1 Dosing Schedule

Morning Dose (with breakfast):

• NAC: 1,800 mg

• ALA: 300 mg

• CoQ10: 150 mg

• Citicoline: 250 mg

• Goji Berry Extract: 250 mg

• AKG: 300 mg

• Vitamin B6: 50 mg

• L-5-MTHF: 800 mcg

• Methyl-cobalamin: 1,000 mcg

• Vitamin D3: 2,000 IU (if deficient)

Evening Dose (with evening meal):

• NAC: 1,800 mg

• ALA: 300 mg

• CoQ10: 150 mg

• Citicoline: 250 mg

• Goji Berry Extract: 250 mg

• AKG: 300 mg

• Magnesium Glycinate: 200 mg

​

​

5.2 Duration

Minimum 45 months of continuous administration (aligned with NAC Attack trial protocol).

​

5.3 Administration Environment

Doses should be taken with meals to minimize gastrointestinal upset from NAC and to enhance absorption of fat-soluble components (CoQ10, ALA, vitamin D3).

​

​

6. Performance Characteristics

​

6.1 Primary Efficacy Endpoints

• Ellipsoid zone (EZ) width preservation: Measurement: SD-OCT horizontal fovea scan. Target: Cumulative EZ loss less than placebo at 45 months.

• Visual acuity preservation: Measurement: Best-corrected visual acuity (BCVA). Target: At least 20/60 maintained.

• Retinal light sensitivity: Measurement: Microperimetry. Target: Less than 3 dB loss from baseline.

• Visual field preservation: Measurement: Humphrey visual field. Target: Less than 20% constriction from baseline.

​

6.2 Secondary Endpoints

• Mitochondrial function: Measurement: Muscle biopsy or blood markers. Target: Improved versus baseline.

• SUMOylation status: Measurement: PBMC SUMO-1/2/3 levels. Target: Maintained within normal range.

• Immune function: Measurement: Interferon signaling, NK cell activity. Target: No microgravity-induced decline.

• Oxidative stress markers: Measurement: Serum glutathione, 8-OHdG. Target: Improved versus baseline.

• Homocysteine levels: Measurement: Serum homocysteine. Target: Less than 10 μmol/L.

​

6.3 Expected Performance Timeline

• 0–6 months: Glutathione elevation; initial antioxidant effects.

• 6–18 months: Stabilization of EZ width loss rate.

• 18–36 months: Measurable preservation of visual function versus natural history.

• 36–45 months: Cumulative EZ preservation; final efficacy determination.

​

​

7. Safety Profile and Monitoring

​

7.1 Known Adverse Effects

• NAC (high dose): Potential adverse effect: Gastrointestinal upset; rare liver enzyme elevation. Management: Divide doses; monitor LFTs at baseline and every 6 months.

• ALA: Potential adverse effect: Hypoglycemia (diabetic patients). Management: Monitor blood glucose; adjust insulin or oral agents.

• CoQ10: Potential adverse effect: Warfarin interaction. Management: Contraindicated with warfarin; monitor INR if necessary.

• Citicoline: Potential adverse effect: Insomnia (if taken late). Management: Administer before 6 PM.

• Magnesium: Potential adverse effect: Loose stools. Management: Reduce dose if persistent.

​

7.2 Required Monitoring

• Liver function tests (ALT, AST, ALP): Frequency: Baseline, 6 months, then annually. Rationale: NAC safety.

• Kidney function (BUN, creatinine): Frequency: Baseline, 6 months, then annually. Rationale: General safety.

• Blood glucose (if diabetic): Frequency: Weekly during initiation, then monthly. Rationale: ALA effect.

• INR (if on anticoagulants): Frequency: Per clinical judgment. Rationale: CoQ10 interaction.

• Ophthalmologic evaluation: Frequency: Every 9 months. Rationale: EZ width, visual acuity, visual field, ERG.

• SUMOylation markers (PBMC): Frequency: Baseline, 12, 24, 36 months. Rationale: Systemic layer monitoring.

​

7.3 Ophthalmologic Monitoring Schedule (Aligned with NAC Attack Protocol)

• Baseline (Month 0): SD-OCT (EZ width), BCVA, visual field, ERG.

• Interim (Month 4.5): Safety assessment.

• Follow-up (Months 9, 18, 27, 36, 40.5, 45): Efficacy and safety assessments.

​

7.4 Discontinuation Criteria

• Significant elevation of liver enzymes (more than 3 times upper limit of normal)

• Severe gastrointestinal intolerance

• Pregnancy or planned pregnancy

• Any new contraindication

​

8. Storage and Stability

• Storage temperature: 15–25°C (room temperature)

• Humidity: Less than 60% relative humidity

• Light protection: Store in original opaque container

• Shelf life: 24 months from manufacture

• Stability monitoring: Quarterly stability testing

​

​

9. Regulatory and Investigational Status

​

9.1 Current Status

This product is an investigational precision nutritional protocol. It is not approved by any regulatory authority for the treatment of retinitis pigmentosa.

​

9.2 NAC Regulatory Status

N-acetylcysteine is approved for acetaminophen overdose but is not approved for retinitis pigmentosa. Its use in RP is investigational and is being evaluated in the Phase III NAC Attack trial (NCT05537220).

​

9.3 Investigational Framework

Use of this protocol should be limited to:

• Clinical trial settings

• Space analogue missions with institutional review board (IRB) approval

• Individualized medical supervision with documented informed consent

​

10. Integrated Performance Summary

• The SAMANSIC-RP Precision Nutritional System represents a dual-layer strategy for biological resilience in artificial microgravity environments.

• Biological Layer (Retinal Protection): NAC serves as the backbone, with Phase I clinical evidence of improved visual acuity and retinal light sensitivity in RP patients, and a Phase III trial now fully recruited to determine long-term efficacy. ALA and CoQ10 address the mitochondrial component of RP, while goji berry extract and citicoline provide additional neuroprotective potential.

• Systemic Layer (SUMOylation and Immune Resilience): The formula supports SUMOylation homeostasis, which is critical for cellular adaptation to microgravity stress. By maintaining SUMO pathway integrity, the protocol aims to prevent the immune dysfunction—including impaired interferon signaling and NK cell function—that microgravity induces.

• Realistic Performance Expectation: The goal is not reversal of vision loss but a measurable slowing of disease progression through antioxidant and mitochondrial support, combined with systemic biological resilience that enables personnel to maintain cognitive performance and physiological adaptation in demanding operational environments.

​

11. References

1. NAC Attack Phase III trial protocol (NCT05537220).

2. Usher Syndrome Coalition. NAC Attack recruitment completion, August 2025.

3. Simulated Microgravity-Induced Changes in SUMOylation and Protein Expression. International Journal of Molecular Sciences. 2025.

4. Single-cell analysis of immune dysfunction in microgravity. Nature Communications. 2024.

5. Artificial Gravity Attenuates the Transcriptomic Response to Spaceflight in the Optic Nerve and Retina. International Journal of Molecular Sciences. 2024.

6. Functional foods for astronauts. ScienceDirect. 2025.

7. NUTRARET trial (folate, B6, vitamin A, zinc, copper, selenium, lutein, zeaxanthin in RP).